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Background
The National Institutes of Health Consensus Conference proposed the term “overlap” graft-ver-
sus-host disease to describe the situation when both acute and chronic graft-versus-host disease
are present. 
Design and Methods
We examined whether the overlap subtype of graft-versus-host disease was associated with a
different prognosis, functional limitations, or patient-reported outcomes compared to “classic”
chronic graft-versus-host disease without any acute features.  
Results
Prospective data were collected from 427 patients from nine centers. Patients were classified as
having overlap (n=352) or classic chronic (n=75) graft-versus-host disease based on reported
organ involvement. Overlap cases had a significantly shorter median time from transplantation
to cohort enrollment (P=0.01), were more likely to be incident cases (P<0.001), and had a lower
platelet count at onset of the graft-versus-host disease (P<0.001). Patients with overlap graft-ver-
sus-host disease had significantly greater functional impairment measured by a 2-minute walk
test, higher symptom burden and lower Human Activity Profile scores. Quality of life was sim-
ilar, except patients with overlap graft-versus-host disease had worse social functioning,
assessed by the Short Form-36. Multivariable analysis utilizing time-varying covariates demon-
strated that the overlap subtype of graft-versus-host disease was associated with worse overall
survival (HR 2.1, 95% CI 1.1–4.7; P=0.03) and higher non-relapse mortality (HR 2.8, 95% CI
1.2–8.3; P=0.02) than classic chronic graft-versus-host disease. 
Conclusions
These findings suggest that the presence of acute features in patients with chronic graft-versus-
host disease is a marker of adverse prognosis, greater functional impairment, and higher symp-
tom burden. 
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Introduction
Chronic graft-versus-host disease (GVHD) is a major late
complication of allogeneic hematopoietic cell transplanta-
tion associated with transplant-related morbidity and
mortality, prolonged immunosuppressive therapy, and
impaired quality of life.1-10 A 2005 National Institutes of
Health (NIH) Consensus Conference discarded the previ-
ous definition of chronic GVHD based on time after
hematopoietic cell transplantation (≥100 days) in favor of
diagnostic criteria based on clinical manifestations.11
According to these proposed NIH criteria, acute GVHD
manifestations (erythematous or maculopapular rash,
nausea and vomiting or diarrhea, and cholestatic hepatitis)
occurring more than 100 days after hematopoietic cell
transplantation are classified as “persistent”, “recurrent”,
or “late onset” acute GVHD depending on the antecedent
history of acute GVHD and absence of other chronic
GVHD manifestations. “Classic chronic” GVHD is defined
by diagnostic manifestations of chronic GVHD without
characteristic features of acute GVHD, and an “overlap”
subtype of chronic GVHD is defined by simultaneous fea-
tures of both chronic and acute GVHD. The proposed
overlap subtype of chronic GVHD was, however, based
on consensus opinion without evidence to support its
prognostic relevance or practical utility. Since the publica-
tion of these proposed criteria, retrospective analyses have
not consistently demonstrated that transplantation out-
comes differ significantly between patients with classic
chronic GVHD and those with overlap GVHD.7,12-14
In order to address whether the overlap subtype of
chronic GVHD has any clinical, functional or prognostic
significance, we analyzed prospectively collected data
from a multicenter observational cohort study.15 Our
hypothesis was that identification of differences would
support continued recognition of the overlap subtype of
chronic GVHD and efforts to distinguish it from late acute
and classic chronic GVHD. 
Design and Methods
Chronic Graft-versus-Host Disease Consortium cohort
The Chronic GVHD Consortium is a prospectively assembled,
multi-center observational cohort study of hematopoietic cell
transplant recipients with chronic GVHD. This protocol was
approved by the Institutional Review Board at each study site. All
subjects signed informed consent. Patients included were allogene-
ic hematopoietic cell transplant recipients aged 2 or older with
chronic GVHD requiring systemic immunosuppressive therapy,
including both those with classic chronic GVHD and those with
overlap syndrome.11 Cases were classified as incident (enrollment
less than 3 months after the diagnosis of chronic GVHD) or preva-
lent (enrollment 3 or more months but less than 3 years after the
diagnosis of chronic GVHD). Exclusion criteria were primary dis-
ease relapse, and inability to comply with study procedures. The
rationale and design of this observational cohort study have been
described in more detail elsewhere.15 Importantly, enrolled
patients do not represent the consecutive series of all chronic
GVHD-affected patients at the participating Consortium centers.      
Clinicians and patients reported standardized information on
chronic GVHD organ involvement and symptoms. Chronic
GVHD severity according to the NIH Chronic GVHD Consensus
was scored using objective criteria for each organ involved, and
summarized to give an overall score of mild, moderate or severe.11
Beyond these measures of chronic GVHD activity, the impact of
chronic GVHD on patients’ functional ability, symptom burden,
and quality of life was comprehensively assessed in this cohort
study. The battery of assessments performed reflect the recom-
mendations of the NIH Consensus Conference, and are described
in the following sections, as well as in the previously published
rationale and design summary of the cohort study.15 One of the
ongoing aims of the Consortium is to define the most parsimo-
nious battery of assessments necessary for chronic GVHD evalua-
tion.
Functional assessments
Functional measures included standardized hand grip strength,
portable spirometry measurement of forced expiratory volume
in one second (FEV1) or FEV1 measured in formal pulmonary
function testing, and the 2-minute walk test. In the assessment of
grip strength, a series of three measurements were made using a
portable electronic dynamometer.16,17 FEV1 was assessed using a
portable spirometer: three measures of FEV1 were recorded after
the patient had been instructed to take a deep breath and then
exhale forcefully and rapidly. Formal pulmonary function test
results were used preferentially if available. In the 2-minute walk
test, the patient was instructed to walk a 50-foot course with 180
degree turns at each end, and total distance covered was record-
ed.17-19
Patient-reported outcomes
The Chronic GVHD Symptom Scale is a 30-item, 7-subscale
symptom scale, which evaluates adverse effects of chronic GVHD
on skin, vitality, lungs, nutritional status, psychological function-
ing, eyes, and mouth symptoms.20 The Human Activity Profile
(HAP) is a 94-item self-reported assessment of energy expenditure
and physical fitness. The instrument was first developed in a pop-
ulation with pulmonary disease, and has since been validated in
hematopoietic cell transplant recipients.21,22 Respondents indicate
whether they have stopped or are still performing activities. A
maximum activity score and adjusted activity score are calculated;
the adjusted activity score is determined by counting how many
activities with lower values than the maximum activity score the
respondent has “stopped doing” and subtracting this from the
maximum activity score. The Functional Assessment of Cancer
Therapy – Bone Marrow Transplantation (FACT-BMT) version 4.0
is a 37-item self-report questionnaire, which includes a ten-item
bone marrow transplant subscale. The instrument measures the
effect of cancer therapy on multiple quality of life domains includ-
ing physical well-being, functional well-being, social/family, and
emotional well being, and specific bone marrow transplantation
concerns. Individual domain scores can be summarized to give a
total FACT-BMT score (including all subscales) or a Functional
Assessment of Cancer Therapy – Trial Outcome Index (FACT-
TOI;  physical well-being + functional well-being + bone marrow
transplant subscale).23,24 The Short Form-36 (SF-36) version 2 is a
36-item self-report questionnaire which assesses health and func-
tioning. The instrument examines the following domains: physical
functioning (PF), role functioning-physical (RP), bodily pain (BP),
general health (GH), vitality (VT), social functioning (SF), role func-
tioning-emotional (RE), and mental health (MH). Two summary
scales from the SF-36 are the physical component score (PCS) and
the mental component score (MCS).25-29
Statistical methods
Standard algorithms were used to compute summary and sub-
scale scores for the Lee symptom scale,20 FACT-BMT,23 SF-36,26,27
and HAP instruments.22 Overlap and classic chronic GVHD were
classified by the proposed NIH criteria.11 Acute GVHD manifesta-
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tions were defined by three organs: skin involvement by erythe-
matous or maculopapular rash, gastrointestinal manifestations of
nausea and vomiting or diarrhea, or liver involvement with abnor-
mal liver function tests. Skin involvement was indicated by an
NIH erythema score greater than 0, or Vienna Skin Score grade 3/4
erythema fraction greater than 0.
Patients’ socio-demographics, transplantation characteristics,
functional test results, clinician-assessed GVHD severity in organs,
and patient-reported outcomes were compared in patients with
overlap syndrome or classic chronic GVHD at enrollment.
Descriptive statistics are presented as medians and ranges for con-
tinuous variables, and as frequencies and percentages for categor-
ical variables. Statistical comparisons between groups were made
with the two-sample t-test for continuous variables, and the c2 test
for categorical variables. A type I error was controlled by consid-
ering a P value of 0.01 or lower as statistically significant.
Overall survival was calculated as months between enrollment
and death, with patients censored at the date they were last
known to be alive. Non-relapse mortality was defined as death
prior to relapse. Relapsed patients were censored at the relapse
date as a competing event, and those without relapse or death
were censored at date they were last known to be alive. Survival
was estimated by the Kaplan-Meier method. The cumulative
incidence of non-relapse mortality was estimated by standard
methods. 
We first utilized Cox regression to compare overall survival
and non-relapse mortality based on enrollment designation of
overlap syndrome versus classic chronic GVHD. Adjusted hazard
ratios were estimated with adjustment for time from transplant
to study enrollment, platelet count at enrollment (<100¥109/L ver-
sus higher), Karnofsky performance status at enrollment (< 80,
80+, missing), patients’ age at transplant (<50 years versus higher),
donor-recipient match and relation (matched related, matched
unrelated, mismatched), donor-patient gender combination
(female into male versus other), prior history of acute GVHD (yes
versus no), and calculated NIH consensus GVHD global severity
score (none/mild, moderate, severe). Hazard ratios were calculat-
ed with classic chronic GVHD patients at enrollment as the ref-
erence. The contributions of the involvement of each acutely
affected organ and organ combinations to overall survival and
non-relapse mortality were also evaluated using Cox regression
analysis. Acute organ involvement was categorized as skin only,
gastrointestinal tract only, liver only, skin and gastrointestinal
tract, skin and liver, gastrointestinal tract and liver, and skin, gas-
trointestinal tract and liver.
We then performed a separate analysis using Cox regression
modeling with time-varying covariates. The following variables
were considered time-dependent: platelet count (<100¥109/L ver-
sus higher), Karnofsky performance status (< 80, 80+, missing),
NIH calculated severity score (none/mild, moderate, severe), and
chronic GVHD subtype (overlap versus classic). Missing time-
dependent variables were imputed from the ‘last observation carry
forward’ method. 
Statistical analyses were conducted using SAS/STAT software,
version 9.2 (SAS Institute, Inc., Cary, NC, USA) and R version 2.9.2
(R Foundation for Statistical Computing, Vienna, Austria). 
Results
Characteristics of overlap and classic chronic 
graft-versus-host disease
Data from 427 participants were included in this analy-
sis representing those patients enrolled in the cohort study
up to September, 2010 from nine centers. The majority
(82%, n=352) had overlap syndrome. Among the 352 sub-
jects with overlap syndrome, skin erythema or macu-
lopapular rash was present in 189 (54%), gastrointestinal
involvement in 129 (37%), and liver involvement in 216
(62%). In addition, 198 (56%) met criteria for acute fea-
tures in only one organ, 126 (36%) for acute features in
two organs, and 28 (8%) for acute features in all three
organs. Only 18% (n=75) had classic chronic GVHD with-
out any acute features.
The subjects were predominantly adults. The median
age at enrollment was 51 years (range, 2-79) for patients
with overlap syndrome and 49 years (range, 17-69) for the
patients with classic chronic GVHD. Baseline socio-demo-
graphic, disease and transplantation variables according to
overlap versus classic status are presented in Table 1. 
Patients with overlap syndrome were more likely to be
incident cases (59% versus 35%, P<0.001), to have a short-
er median time from transplantation to enrollment (11.9
months versus 19.8 months, P=0.01), and to have lower
platelet counts at the onset of chronic GVHD (P<0.001).
Neither clinician-reported nor patient-reported global
severity of GVDH was associated with overlap designa-
tion. Involvement of joints and fascia was more common
in classic chronic GVHD. The distribution of mouth, eye,
lung and genital involvement did not differ significantly
between overlap and classic chronic GVHD (Table 1).
Association between overlap chronic 
graft-versus-host disease and morbidity
Patients with overlap syndrome performed significantly
less well on the 2-minute walk test. In addition the FEV1
was lower in patients with overlap syndrome (Ttable 2).
Differences in patient-reported quality of life between
those with overlap syndrome and classic chronic GVHD
were minimal, although those with overlap syndrome had
inferior SF-36 social functioning scores (5 points lower, in
keeping with a clinically meaningful 0.5 standard devia-
tion difference). Patients with overlap syndrome and clas-
sic chronic GVHD had similar chronic GVHD symptom
scale item and summary scores except that nutrition and
skin symptom scale scores were significantly worse in
those with overlap syndrome, as expected. HAP maxi-
mum and adjusted activity scores and modified maximum
and adjusted activity scores were significantly inferior for
those with overlap GVHD (Table 2).
Association between overlap chronic graft-versus-host
disease and mortality – analysis according to cohort
enrollment data
Of the 427 enrolled patients, 413 had follow-up beyond
the baseline visit and could be evaluated for survival out-
comes. The median follow-up time after enrollment for
patients with overlap GVHD was 17.1 months, while that
for patients with classic chronic GVHD was 19.0 months.
Figures 1 and 2 illustrate overall survival and non-relapse
mortality according to classic GVHD versus overlap GVHD
status at enrollment. The 2-year overall survival estimate
for patients with overlap syndrome was 77% versus 94%
for those with classic GVHD. The 2-year non-relapse mor-
tality estimates were 20% and 4% for those with overlap
GVHD and classic GVHD, respectively. Causes of death of
patients with overlap and classic chronic GVHD were,
respectively, GVHD-related (n=27, n=0), relapse (n=18,
n=0), unknown (n=3, n=1), and other (n=14, n=3). After
Overlap subtype of chronic GVHD
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Table 1. Baseline characteristics of patients with overlap syndrome versus classic
chronic GVHD.
Characteristics Overlap (N = 352) Classic (N = 75)
N. Count Percent N. Count Percent P value*
Site 352 75 0.84
Fred Hutchinson 164 47 39 52
Cancer Research Center
University of Minnesota 41 12 8 11
Dana-Faber Cancer institute 42 12 9 12
Stanford University 50 14 8 11 
Medical Center
Northwestern Childrens 12 3 1 1
Hospital
Vanderbilt University 25 7 8 11 
Medical Center
Medical College of Wisconsin 12 3 1 1
Washington University 2 1 0 0
Medical Center
Moffitt Cancer Center 4 1 1 1
Case type 352 75 <0.001
Incident 206 59 26 35
Prevalent 146 41 49 65
Adults 352 339 96 75 74 99 0.30
Male 352 200 57 75 48 64 0.25
Race 352 75 0.82
White 316 90 68 91
Non-white 36 10 7 9
Hispanic 352 19 5 75 1 1 0.16
Diagnosis at transplant 352 75 0.89
Acute myeloid leukemia 114 32 28 38
Acute lymphoblastic leukemia 45 13 9 12
Chronic myeloid leukemia 16 5 4 5
Chronic lymphocytic leukemia 26 7 4 5
Myelodysplastic syndrome 56 16 7 10
Non-Hodgkin’s lymphoma 52 15 11 15
Hodgkin lymphoma 12 3 4 5
Multiple myeloma 17 5 4 5
Aplastic anemia or other 14 4 4 5
Disease status 350 74 0.94
Early 114 33 25 34
Intermediate 154 44 33 44
Advanced 82 23 16 22
Transplant source 352 75 0.73
Peripheral blood 307 87 67 90
Bone marrow 28 8 4 5
Cord blood 17 5 4 5
Transplant type 351 75 0.62
Myeloablative 195 56 44 59
Non-myeloablative 156 44 31 41
Patient CMV positive 351 200 57 73 43 59 0.76
Donor CMV positive 348 137 39 73 29 40 0.95
Donor match 352 74 0.13
Matched related 150 43 39 53
Mismatched 63 18 7 9
Matched unrelated 139 39 28 38
Donor gender 348 74 0.82
Female into male 99 28 22 30
Other 249 72 52 70
Had prior acute GVHD 352 235 67 75 46 61 0.37
NIH consensus severity score 352 75 0.36
None 0 0 2 3
Mild 36 10 7 9
Moderate 197 56 47 63
Severe 119 34 19 25
Clinician-assessed sev. score 352 75 0.19
Mild 166 47 43 58
Moderate 150 43 28 37
Severe 36 10 4 5
Patient-reported severity score 304 60 0.30
None 9 3 1 2
Mild 159 52 33 55
Moderate 108 36 24 40
Severe 28 9 2 3
Skin score 352 75 NA**
None 118 34 42 56
Mild 96 27 7 9
Moderate 85 24 19 26
Severe 53 15 7 9
Mouth score 352 75 0.02
None 134 38 31 41
Mild 161 45 41 55
Moderate 48 14 3 4
Severe 9 3 0 0
GI tract score 352 75 NA**
None 223 63 75 100
Mild 102 29 0 0
Moderate 25 7 0 0
Severe 2 1 0 0
Eye score 352 75 0.46
None 182 51 38 50
Mild 101 29 26 35
Moderate 60 17 9 12
Severe 9 3 2 3
Joints and fascia score 352 75 <0.001
None 262 75 37 49
Mild 64 18 23 31
Moderate 22 6 14 19
Severe 4 1 1 1
Lung score 352 75 0.51
None 177 50 36 48
Mild 119 34 30 40
Moderate 48 14 8 11
Severe 8 2 1 1
Liver score 350 75 NA**
None 134 38 75 100
Mild 161 46 0 0
Moderate 53 15 0 0
Severe 2 1 0 0
Genital score 314 71 0.12
None 282 90 58 82
Mild 18 6 6 8
Moderate 10 3 5 7
Severe 4 1 2 3
Platelet count (¥109/L) 344 73 <0.001
at enrollment
< 100¥109/L 92 27 5 7
≥ 100¥109/L 252 73 68 93
Karnofsky performance status 306 62 0.06
at enrollment
< 80 118 39 16 26
≥ 80 188 61 46 74
Months from transplant 
to enrollment
Median (range) 352 11.9 (2.9-61.7) 75 19.8 (3.1-299.1) 0.01
*To get valid Chi-square tests, none and mild groups were collapsed together for NIH consensus
and patient-reported severity scores; moderate and severe groups were collapsed together for indi-
vidual organ scores. **Comparisons for these organs are not meaningful because they are used
to define overlap syndrome. CMV, cytomegalovirus; HLA, human leukocyte antigen; GI: gastroin-
testinal.
continued in next column
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adjusting for known chronic GVHD risk factors, the over-
lap subtype of chronic GVHD at enrollment was associat-
ed with inferior overall survival (HR 2.8, 95% CI 1.1–9.3;
P=0.03) and higher non-relapse mortality (HR 4.4, 95% CI
1.3–27.2; P=0.01). Among the covariates included in these
models, platelet count at enrollment and NIH global
chronic GVHD severity at enrollment were also signifi-
cantly associated with overall survival and non-relapse
mortality. 
We explored whether the higher non-relapse mortality
and lower overall survival observed in the patients with
the overlap subtype of GVHD were associated with par-
ticular combinations of acute features. A total of 424
patients were included in this analysis, after excluding
three patients with missing organ scores. Compared with
classic chronic GVHD, statistically significant differences
were found among all organ involvement combinations of
overlap except when skin and gastrointestinal tract were
involved together, and when liver and gastrointestinal
tract were involved together. The involvement of all three
organs was associated with the greatest hazard for overall
survival (HR 6.8, 95% CI 2.1–22.8; P=0.002) and non-
relapse mortality (HR 11.9, 95% CI 2.5–57.6; P=0.002).
Table 3 shows the overall survival analysis. Results of the
non-relapse mortality analysis were similar and are not
shown.
Association between overlap chronic graft-versus-host
disease and mortality – time-dependent analysis 
Acknowledging that overlap and classic chronic GVHD
are not fixed categories and that disease manifestations
vary with time and intensity of immune suppressive ther-
apy, we performed an analysis in which chronic GVHD
subtype (overlap versus classic) was considered a time-vary-
ing covariate. The overlap subtype of GVHD was associat-
ed with worse overall survival (HR 2.1, 95% CI 1.1–4.7;
P=0.03) and higher non-relapse mortality (HR 2.8, 95% CI
1.2–8.3; P=0.02) than classic chronic GVHD. Among other
covariates considered in the overall survival analysis,
platelet count less than 100¥109/L (HR 3.4, 95% CI 1.9–6;
P<0.001), Karnofsky performance status less than 80 (HR
2.4, 95% CI 1.4–4.1; P=0.002), and severe NIH global
severity score (HR 5.1, 95% CI 1.5–32.1, P=0.03) were
associated with overall survival. In the analysis of non-
relapse mortality, platelet count less than 100¥109/L (HR
3.1, 95% CI 1.6–5.9, P<0.001), and Karnofsky performance
status less than 80 (HR 2.2, 95% CI 1.2–4.2, P=0.01) were
associated with non-relapse mortality. 
Discussion
From the 2005 NIH Consensus Development Project on
GVHD, a proposed overlap subtype of chronic GVHD
emerged. This recommendation was controversial, with
some doubting whether recognition of the overlap sub-
type of GVHD had practical clinical utility or any associa-
tion with meaningful transplant outcomes. Others pointed
out that prior studies in chronic GVHD had identified
extensive skin involvement,30-32 elevated bilirubin,10,33 gas-
trointestinal tract involvement,32 and progressive onset
from acute GVHD30,33,34 as poor prognostic findings.
Studies using retrospective review of medical records
failed to settle the controversy. Our findings based on
prospectively collected data support the recognition of the
overlap subtype of chronic GVHD as an important condi-
tion with an adverse prognosis, functional impairment,
and significantly higher symptom burden. 
Recognition of the overlap subtype of chronic GVHD
appears to have several implications: as patients with
Overlap subtype of chronic GVHD
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Table 2. Functional characteristics of overlap versus classic chronic GVHD.
Characteristics Overlap (N = 352) Classic (N = 75) P-value
n Median Range n Median Range
Walk test (feet) 298 495 170-1150 69 540 300-1140 <0.001
Grip strength (lb) 337 59.7 2.0-167.0 73 63.3 15.3-139.0 0.43
Portable spirometer 316 2.4 0.2-5.6 68 2.7 0.2-5.2 0.02
FEV1 (L/sec)
SF36-physical 292 42.3 14.9-57.0 60 44.4 17.0-57.0 0.07
functioning
SF36-role physical 294 37.3 17.7-56.9 61 37.3 17.7-56.9 0.02
SF36-bodily pain 294 46.1 19.9-62.1 62 43.9 24.9-62.1 0.20
SF36-general health 291 40.1 18.6-63.9 62 41.7 16.2-63.9 0.52
SF36-vitality 295 45.8 20.9-70.8 62 47.4 24.0-70.8 0.13
SF36-social functioning 295 40.5 13.2-56.8 62 45.9 13.2-56.8 0.01
SF36-role emotional 293 48.1 9.2-55.9 61 48.1 9.2-55.9 0.18
SF36-mental health 295 50.0 13.4-64.1 62 51.4 16.2-64.1 0.75
SF36-physical 286 39.3 15.5-59.4 60 40.1 16.6-60.7 0.25
component scale
SF36-mental 286 49.8 15.3-65.8 60 53.0 25-68.4 0.25
component scale
FACT-physical 294 22 1-28 62 23 6-28 0.39
FACT-social/family 293 23 0-28 62 24 6-28 0.37
FACT-emotional 293 20 6-24 62 19 4-24 0.20
FACT-functional 293 16 2-28 62 18 4-27 0.12
FACT-BMT subscale 293 27 11-39 62 28 11.1-40 0.23
FACT-BMT trial 293 64.7 22-94 62 65.7 25-93 0.18
outcome index
FACT-G 291 79 29-108 62 81.5 23-101 0.37
FACT-BMT total score 291 106 49-146 62 108 36-138 0.30
Symptom scale-skin 308 15 0-100 63 10 0-80 0.005
Symptom scale-energy 307 32.1 0-100 63 32.1 3.6-82.1 0.66
Symptom scale-lung 308 5 0-70 63 5 0-40 0.47
Symptom scale-eye 307 25 0-100 63 25 0-100 0.93
Symptom 307 5 0-70 63 0 0-20 <0.001
scale-nutrition
Symptom 305 16.7 0-83.3 63 25 0-100 0.16
scale-psychological
Symptom scale-mouth 308 12.5 0-100 63 0 0-100 0.09
Symptom scale 308 20.7 0-65.3 63 18.1 4.1-56.6 0.25
summary
HAP-maximum 293 70 36-94 62 78 52-94 <0.001
activity score
HAP-adjusted 293 59 14-94 62 70 30-94 <0.001
activity score
Modified 293 52 19-74 62 58 38-74 <0.001
HAP-maximum 
activity score
Modified 293 46 11-74 62 54 22-74 <0.001
HAP-adjusted 
activity score
acute features have significantly higher non-relapse mor-
tality and lower overall survival, they represent a vulnera-
ble group who may benefit from different or more aggres-
sive therapeutic interventions. The optimal management
of these patients is not known, but they are expected to
have high non-relapse mortality and poor overall survival
under current practices. 
We found that patients with overlap syndrome suffer
significant and diverse functional impairments compared
to those with classic chronic GVHD, including significant-
ly worse performance on the 2-minute walk test, and
lower self-reported HAP scores. These data suggest a sys-
temic functional impairment beyond the more direct ram-
ifications of concurrent acute GVHD manifestations such
as skin erythema or maculopapular rash, gastrointestinal
tract and liver involvement. The similar incidence of prior
acute GVHD in the overlap and classic chronic GVHD
groups argues that this functional impairment is not due to
extended or more intensive immunosuppressive treatment
for acute GVHD in the overlap group. 
While overall symptom burden was comparable
between patients with overlap GVHD and classic chronic
GVHD, significantly worse symptoms were reported by
patients with overlap syndrome in intuitive domains
including skin and nutrition. Individual domain and sum-
mary scores from both the SF-36 and FACT-BMT instru-
ments largely demonstrated similar reported quality of
life. Those with overlap syndrome had worse SF-36 social
functioning. As items within this domain largely encom-
pass emotional support, relationships, and communica-
tion, the data suggest another particular area of vulnerabil-
ity for such patients, and a potential key area for targeted
support and intervention.
Finally, we classified patients as having overlap or classic
GVHD in this analysis according to the presence of objec-
tive manifestations of concurrent acute GVHD, as we
found that clinicians were not accurately applying the NIH
definition of overlap. At enrollment, clinicians identified
152 as having overlap chronic GVHD (39%), and 242 as
having classic chronic GVHD (61%), after excluding 32
patients reported as having late acute GVHD and one
patient reported as not having GVHD. Of the 152 reported
as having overlap syndrome, 131 (86%) had acute GVHD
manifestations recorded, while 21 (14%) did not. Of the
242 classified as having classic chronic GVHD by clini-
cians, 189 (78%) objectively had acute manifestations,
while 53 (22%) did not. Agreement between clinician des-
ignations and classification based on whether or not acute
GVHD manifestations were reported was poor, with a
simple kappa statistic of 0.07. These data speak for the
need for further education and consistency in adherence to
the proposed NIH Consensus definition of overlap sub-
type of chronic GVHD. We acknowledge that inaccurate
classification by clinicians may affect treatment decisions
and outcomes. However, there are no current guidelines
for tailored therapy for classic or overlap subtype of
chronic GVHD, and hence clinicians provided what con-
stitutes best clinical care based on current evidence. These
data, however, indicate an excess risk associated with the
overlap subtype, and argue for rigorous studies to define
the best treatment approaches for these patients. 
The major strength of this analysis results from the large
size of the cohort and the study design in which standard-
ized comprehensive data were gathered prospectively.
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Table 3. Effect of acute organ involvement on overall survival (N=424).
Organ(s) Estimate P value Hazard Ratio* 95% Hazard
involved Ratio CI
Skin only 1.2 0.03 3.4 1.1-10.6
GI only 1.4 0.03 4.0 1.2-13.7
Liver only 1.3 0.02 3.8 1.2-11.6
Skin and GI 0.8 0.35 2.2 0.4-12.3
Skin and liver 1.5 0.008 4.5 1.5-13.4
GI and liver 1.2 0.06 3.4 0.9-12.0
Skin, GI and liver 1.9 0.002 6.8 2.1-22.8
*reference (HR of 1) is classic chronic GVHD, with no features of acute GVHD. GI: gas-
trointestinal tract.
Figure 1. Overall survival according to overlap versus classic chronic
GVHD.
Figure 2. Non-relapse mortality according to overlap versus classic
chronic GVHD.
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These data demonstrate the relevance of the overlap des-
ignation, and address major shortcomings of previously
reported retrospective analyses. The analysis highlights
the importance of the overlap subtype, and calls for
advances in the management of these patients. However,
we acknowledge the following potential limitations of
this analysis. First, patients participating in this cohort
study under-represent the total burden of chronic GVHD
cases at each of the respective participating centers. While
bias in selection of cases for participation in this study
could influence results, this concern must be considered in
the context of the availability of comprehensive data
which is only possible in a prospective study. Additionally,
it is important to recognize that the distribution of classic
and overlap cases observed in this cohort study reflects
only those enrolled, and thus cannot be extrapolated to
the entire population of patients with chronic GVHD.
Second, we acknowledge that overlap and classic chronic
GVHD are not fixed, but rather may change over time
according to disease activity and intensity of immune sup-
pressive therapy. This concern may threaten the integrity
of the overall survival and non-relapse mortality analyses
based on cohort enrollment data. We addressed this con-
cern through the conduct of separate analyses in which
chronic GVHD subtype (overlap versus classic) was treated
as a time-varying covariate. Results of these time-depen-
dent analyses were similar to those using enrollment data,
hence providing uniformity in our conclusions. Next, we
acknowledge that the majority of subjects were enrolled at
four centers. We performed the major study analyses sep-
arately on data from only these centers, and did not detect
major changes in our reported conclusions. Finally, we rec-
ognize a potential risk for GVHD misclassification that
may affect these results. Specifically, objective manifesta-
tions scored as chronic GVHD by clinicians were not all
biopsy-confirmed, and we recognize that some manifesta-
tions (e.g. abnormal liver function tests) may result from
alternative sources. This is, however, in keeping with chal-
lenges inherent in clinical practice in transplantation and
should not be considered a particular weakness of this
study.
We conclude that the overlap subtype of chronic
GVHD, defined by the presence of features of both acute
and chronic GVHD, is significantly associated with higher
morbidity and mortality. These findings support the
importance of the proposed designation, and argue for
increased awareness and accurate classification in clinical
practice and research.
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